SAN DIEGO, July 30, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson’s Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). [Read more…]